News Articles

Takeda Agrees to Divest Select OTC and Non-core Assets to Acino for Over $200 Million USD OSAKA, Japan -Tuesday 15 October 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select over-the-counter (OTC) and prescription pharmaceutical assets in a number of Near East, Middle East and Africa (NEMEA)...

New Data Presented at World Sleep Congress Demonstrate Early Signs of Efficacy for TAK-925, a Selective Orexin Type-2... -Friday 27 September 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) announced results of a Phase 1 clinical proof of concept study of the novel investigational compound TAK-925, a selective orexin type-2 receptor (OX2R) agonist, in individuals with narcolepsy type 1 (NT1)....

First Head-to-Head Biologic Study in Ulcerative Colitis Published in The New England Journal of... -Friday 27 September 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced further results from the VARSITY study, which demonstrated the superiority of the gut-selective biologic vedolizumab (Entyvio®) to the anti-tumor necrosis factor-alpha (anti-TNFα)...

New England Journal of Medicine Publishes Results of a Phase 2 Trial Evaluating Takeda’s TAK-620 (Maribavir)... -Tuesday 24 September 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the New England Journal of Medicine has published results of a Phase 2, randomised, 12-week, open-label study of TAK-620 (maribavir), an investigational, orally bioavailable...

Takeda Recognized in the 2019 Dow Jones Sustainability World Index -Thursday 19 September 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO:4502/NYSE:TAK) today announced that it has been named in the 2019 Dow Jones Sustainability World Index, achieving more than double the average overall industry score. In addition, Takeda was named for the 10th...

Takeda Announces FY2019 Key Performance Indicators Aligned with Shareholder Value Creation and Focused on Successful... -Friday 2 August 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO: 4502/NYSE: TAK) today announces that the Takeda Board of Directors has approved key performance indicators (KPIs) to be included in both the company’s short-term and long-term incentive plans for fiscal year 2019,...

Takeda Reports Strong First Quarter FY2019 Results and Raises Guidance for the Full Year -Friday 2 August 2019

Revenue 849.1 billion yen, up +88.8% versus prior year mainly due to acquisition of Shire, with solid performance of 14 global growth brands Strong start with Core Operating Profit* of 283.0 billion, up +142.3% versus FY2018 Q1 and Underlying Core Operating Profit Margin of 32.4% Shire...

Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week... -Monday 22 July 2019

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced top-line results from the VISIBLE 2 clinical trial evaluating the efficacy and safety of an investigational subcutaneous (SC) formulation of the gut-selective biologic vedolizumab as...

Takeda Continues Ongoing Inclusion in the FTSE4Good Developed Index & MSCI ESG Leaders Index -Thursday 11 July 2019

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO:4502/NYSE:TAK) today announced that it has been selected for the 15th consecutive year by the FTSE4Good Developed Index, one of the world’s premier indices for Socially Responsible Investment (SRI), created by...

Takeda Unveil New Data from the PROPEL Study at ISTH 2019, Reinforcing the Potential Benefit for Personalized... -Monday 8 July 2019

- Updated results from the Phase IIIb/IV PROPEL Study show that pharmacokinetic (PK)-driven dosing may be used to achieve FVIII target trough levels of 8–12%; and that selecting a patient-appropriate target FVIII level plus adjusting a dosing regimen to that patient’s PK characteristics,...

Takeda to Demonstrate Global Leadership in Hematology at ISTH 2019 -Wednesday 3 July 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”), the global biotechnology leader in rare diseases, will present research covering a broad range of rare bleeding disorders at the 27th Annual International Society on Thrombosis and Haemostasis Congress...

Takeda Completes Sale of Xiidra® to Novartis -Monday 1 July 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its sale of its Xiidra® (lifitegrast ophthalmic solution) 5% product to Novartis for $3.4 billion upfront in cash and up to an additional $1.9 billion in potential...

Takeda Selects Five New Partnerships for Annual Global Corporate Social Responsibility (CSR) Program, Supporting Disease... -Friday 28 June 2019

Takeda’s founding mission to serve patients, wherever they are, drives its increased commitments to disease prevention, capacity building, and access to healthcare in developing and emerging countries, in partnership with the global community. Through its annual Global CSR Program,...

Takeda Provides Update on TOURMALINE-AL1 Phase 3 Trial in AL Amyloidosis -Sunday 9 June 2019

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) today announced that the Phase 3 TOURMALINE-AL1 clinical trial in patients with relapsed or refractory systemic light-chain (AL) amyloidosis did not meet the first of two primary endpoints. Treatment with...

Takeda Presents Results from Lung Portfolio Including Phase 1/2 Study of TAK-788 in a Rare Form of NSCLC and New Data on... -Friday 7 June 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that new data for TAK-788 will be presented during an oral session at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting on Monday, June 3 at 10:12 a.m. CT in Chicago. Results from a...

Takeda Makes First Private Sector Pledge for Global Fund Replenishment -Tuesday 4 June 2019  

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (“Takeda”) (TSE:4502/NYSE:TAK) today became the first private sector company to announce a financial commitment to the Global Fund’s Sixth Replenishment. The new pledge, consisting of JP ¥ 1 billion over five years, builds on...

New Ad-hoc Analysis of Phase 3 HELP Study™ Evaluates Prevention of HAE Attacks with... -Monday 3 June 2019

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced new data from an ad-hoc analysis of the Phase 3 HELP Study™, designed to evaluate the onset of action for TAKHZYRO® (lanadelumab) during days 0-69 of treatment. The analysis suggests...

Takeda to Showcase Growing Pipeline and Diversified Portfolio of Oncology Products at Upcoming Scientific Congresses -Monday 20 May 2019

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) today announced that the company will present data at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 31-June 4 in Chicago and the 24th Congress of the European Hematology...

New Exploratory Data from VARSITY, First Head-to-Head Ulcerative Colitis Biologic Study Which Demonstrated Superiority... -Monday 20 May 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced further results from the Phase 3b head-to-head VARSITY study, which demonstrated that the gut-selective biologic vedolizumab (Entyvio®) was superior to the anti-tumor necrosis factor-alpha...

Takeda and London School of Hygiene & Tropical Medicine Establish "Takeda Chair in Global Child Health" -Saturday 18 May 2019  

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) and the London School of Hygiene & Tropical Medicine (LSHTM) will announce today at the evening reception, hosted by the Embassy of Japan in the United Kingdom, the establishment of the Takeda Chair in...